Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report report published on Tuesday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Price Performance

Shares of Enzo Biochem stock opened at $0.71 on Tuesday. The company’s fifty day simple moving average is $1.07 and its two-hundred day simple moving average is $1.10. Enzo Biochem has a 12-month low of $0.68 and a 12-month high of $1.50.

Enzo Biochem (NYSE:ENZ) last released its quarterly earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative return on equity of 11.84% and a negative net margin of 81.73%.

Enzo Biochem Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were given a dividend of $0.10 per share. The ex-dividend date was Friday, November 15th. This represents a $0.40 dividend on an annualized basis and a yield of 56.14%.

Hedge Funds Weigh In On Enzo Biochem

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC grew its stake in shares of Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after buying an additional 11,742 shares during the last quarter. XTX Topco Ltd boosted its holdings in Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after acquiring an additional 13,735 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after acquiring an additional 64,417 shares in the last quarter. Finally, BBR Partners LLC purchased a new stake in shares of Enzo Biochem in the third quarter worth $112,000. Institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.